BIOFILCHEM vs PGHL: Stock Comparison

Biofil Chemicals & Pharmaceuticals Limited vs Procter & Gamble Health Limited

Live data: 22 July 2026, 3:06 PM IST • Source: NSE and company filings

Procter & Gamble Health Limited is the larger company by market capitalisation. Procter & Gamble Health Limited shows a higher ROE, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Biofil Chemicals & Pharmaceuticals Limited and Procter & Gamble Health Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, BIOFILCHEM is more favourable on 0 of 11 scored metrics and PGHL on 11These counts are context-free and are not an overall rating.

Key Differences

Market Cap
PGHL is the larger company
₹11,208 Cr vs ₹54 Cr
EPS
PGHL has higher earnings per share
₹196.64 vs ₹1.71
Dividend Yield
PGHL has a higher dividend yield
2.34% vs 0%
Revenue Growth (TTM YoY)
PGHL has faster revenue growth
19.1% vs -9.3%
EPS Growth (TTM YoY)
PGHL has faster EPS growth
54.6% vs 10.8%
Qtr Sales Growth
PGHL has stronger quarterly sales growth
19.1% vs -9.34%
Qtr Profit Growth
PGHL has stronger quarterly profit growth
54.6% vs 5%
ROE
PGHL has a higher ROE
61.6% vs 13.8%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricBIOFILCHEMPGHL
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricBIOFILCHEMPGHL
Live Price₹33.5₹6,740
Day Change-0.53%-0.58%
Volume1,1044,692
52-Week High₹46.34₹6,975
52-Week Low₹25.6₹4,707
Distance from 52W High-27.71%-3.37%

Valuation

MetricBIOFILCHEMPGHL
Market Cap₹54 Cr₹11,208 Cr
P/E Ratio34.28x
P/B Ratio21.36x
EPS₹1.71₹196.64
Book Value₹13.21₹316.01
Dividend Yield0%2.34%

Growth

MetricBIOFILCHEMPGHL
Revenue Growth (TTM YoY)-9.3%19.1%
EPS Growth (TTM YoY)10.8%54.6%
Qtr Sales Growth-9.34%19.1%
Qtr Profit Growth5%54.6%

Profitability & Leverage

MetricBIOFILCHEMPGHL
ROE13.8%61.6%
ROCE15.8%83.5%
Net Margin9.81%23.22%
Operating Margin2.29%32.4%
Debt to Equity0.14x0.02x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricBIOFILCHEMPGHL
Promoter Holding46.79%0%
FII Holding0%6.33% 0.13 pp
DII Holding0.08%12.44% 1.23 pp
Public Holding53.13%29.42% 1.11 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Biofil Chemicals & Pharmaceuticals Limited and Procter & Gamble Health Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.